{"transactions":[{"id":4618474,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-09-15T21:23:13.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":72.13,"value":72130.0,"ownership":{"direct":true},"balance_after":8184,"source":{"system":"sec-edgar","filing":"0001061983-26-000095","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585160/000106198326000095/form4.xml","form_type":"4"}},{"id":4616469,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-09-11T23:12:26.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":74.66,"value":74660.0,"ownership":{"direct":true},"balance_after":9184,"source":{"system":"sec-edgar","filing":"0001061983-26-000093","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585160/000106198326000093/form4.xml","form_type":"4"}},{"id":762475,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2026-05-27T23:09:20.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":4301,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4301,"derivative":{"exercise_price":77.15,"exercise_date":"2026-06-27","expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":4301},"source":{"system":"sec-edgar","filing":"0001061983-26-000056","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000056/form4.xml","form_type":"4"}},{"id":762474,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-27T23:09:20.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":2851,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10184,"source":{"system":"sec-edgar","filing":"0001061983-26-000056","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000056/form4.xml","form_type":"4"}},{"id":940754,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-01-13T01:56:39.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":7700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"RSUs vest on January 12, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSUs vest on January 12, 2027."}],"balance_after":7700,"derivative":{"exercise_date":"2027-01-12","expiration_date":"2027-01-12","underlying":"Common Stock","underlying_shares":7700},"source":{"system":"sec-edgar","filing":"0001193125-26-010859","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1585160/000119312526010859/ownership.xml","form_type":"4"}},{"id":940753,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T01:56:39.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":11500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options vest on January 12, 2027."}],"balance_after":11500,"derivative":{"exercise_price":23.16,"exercise_date":"2027-01-12","expiration_date":"2036-01-11","underlying":"Common Stock","underlying_shares":11500},"source":{"system":"sec-edgar","filing":"0001193125-26-010859","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585160/000119312526010859/ownership.xml","form_type":"4"}},{"id":1068602,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-13T00:30:04.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":62000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options vest in 36 equal monthly installments starting one month after grant date of August 11, 2025."}],"balance_after":62000,"derivative":{"exercise_price":12.44,"expiration_date":"2035-08-10","underlying":"Common Stock","underlying_shares":62000},"source":{"system":"sec-edgar","filing":"0000950170-25-107543","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1585160/000095017025107543/ownership.xml","form_type":"4"}},{"id":1149744,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2025-05-14T23:27:29.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":10880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Comprised of stock options that will vest monthly in equal installments over a period commencing on the grant date and ending on the earlier to occur of (x) the one-year anniversary of the date of the grant and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors."}],"balance_after":10880,"derivative":{"exercise_price":30,"exercise_date":"2025-06-16","expiration_date":"2035-05-13","underlying":"Common Stock","underlying_shares":10880},"source":{"system":"sec-edgar","filing":"0001127602-25-014356","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760225014356/form4.xml","form_type":"4"}},{"id":1149743,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-14T23:27:29.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":7333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Comprised of restricted stock units (\"RSUs\") that will vest in one installment on the earlier to occur of (x) the one-year anniversary of the grant date and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. RSUs convert to shares of common stock on a 1:1 basis upon vesting."}],"balance_after":7333,"source":{"system":"sec-edgar","filing":"0001127602-25-014356","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760225014356/form4.xml","form_type":"4"}},{"id":1274689,"issuer":{"id":3528,"kind":"organization","name":"CYTOKINETICS INC","symbol":"CYTK"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2025-02-11T13:26:25.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":25538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Initial grant to new director. Stock Options vest monthly over 3-years from the date of grant."}],"balance_after":25538,"derivative":{"exercise_price":42.21,"exercise_date":"2025-03-10","expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":25538},"source":{"system":"sec-edgar","filing":"0001127602-25-003989","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061983/000112760225003989/form4.xml","form_type":"4"}},{"id":1657474,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-02-06T21:08:17.000Z","date":"2024-02-02","kind":"exercise","planned":false,"acquired":false,"shares":400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":11787,"derivative":{"exercise_price":378.98,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001968202-24-000053","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000053/edgardoc.xml","form_type":"4"}},{"id":1657473,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-02-06T21:08:17.000Z","date":"2024-02-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":281,"price":956.65,"value":268818.65,"ownership":{"direct":true},"balance_after":23693,"source":{"system":"sec-edgar","filing":"0001968202-24-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000053/edgardoc.xml","form_type":"4"}},{"id":1657472,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-02-06T21:08:17.000Z","date":"2024-02-02","kind":"exercise","planned":false,"acquired":true,"shares":400,"price":378.98,"value":151592.0,"ownership":{"direct":true},"balance_after":23974,"source":{"system":"sec-edgar","filing":"0001968202-24-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000053/edgardoc.xml","form_type":"4"}},{"id":1662926,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-02-02T21:02:11.000Z","date":"2024-01-31","kind":"exercise","planned":false,"acquired":false,"shares":400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":12187,"derivative":{"exercise_price":378.98,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001968202-24-000045","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000045/edgardoc.xml","form_type":"4"}},{"id":1662925,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-02-02T21:02:11.000Z","date":"2024-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":282,"price":953.42,"value":268864.44,"ownership":{"direct":true},"balance_after":23574,"source":{"system":"sec-edgar","filing":"0001968202-24-000045","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000045/edgardoc.xml","form_type":"4"}},{"id":1662924,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-02-02T21:02:11.000Z","date":"2024-01-31","kind":"exercise","planned":false,"acquired":true,"shares":400,"price":378.98,"value":151592.0,"ownership":{"direct":true},"balance_after":23856,"source":{"system":"sec-edgar","filing":"0001968202-24-000045","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000045/edgardoc.xml","form_type":"4"}},{"id":1671431,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-01-25T21:17:25.000Z","date":"2024-01-24","kind":"exercise","planned":false,"acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":12587,"derivative":{"exercise_price":378.98,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001968202-24-000040","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000040/edgardoc.xml","form_type":"4"}},{"id":1671430,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-01-25T21:17:25.000Z","date":"2024-01-23","kind":"exercise","planned":false,"acquired":false,"shares":1100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":13087,"derivative":{"exercise_price":378.98,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":1100},"source":{"system":"sec-edgar","filing":"0001968202-24-000040","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000040/edgardoc.xml","form_type":"4"}},{"id":1671429,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-01-25T21:17:25.000Z","date":"2024-01-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":352,"price":951.26,"value":334843.52,"ownership":{"direct":true},"balance_after":23456,"source":{"system":"sec-edgar","filing":"0001968202-24-000040","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000040/edgardoc.xml","form_type":"4"}},{"id":1671428,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-01-25T21:17:25.000Z","date":"2024-01-24","kind":"exercise","planned":false,"acquired":true,"shares":500,"price":378.98,"value":189490.0,"ownership":{"direct":true},"balance_after":23808,"source":{"system":"sec-edgar","filing":"0001968202-24-000040","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000040/edgardoc.xml","form_type":"4"}},{"id":1671427,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-01-25T21:17:25.000Z","date":"2024-01-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":776,"price":948.5,"value":736036.0,"ownership":{"direct":true},"balance_after":23308,"source":{"system":"sec-edgar","filing":"0001968202-24-000040","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000040/edgardoc.xml","form_type":"4"}},{"id":1671426,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-01-25T21:17:25.000Z","date":"2024-01-23","kind":"exercise","planned":false,"acquired":true,"shares":1100,"price":378.98,"value":416878.0,"ownership":{"direct":true},"balance_after":24084,"source":{"system":"sec-edgar","filing":"0001968202-24-000040","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000040/edgardoc.xml","form_type":"4"}},{"id":1677181,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-01-18T21:02:18.000Z","date":"2024-01-17","kind":"exercise","planned":false,"acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":14187,"derivative":{"exercise_price":378.98,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001968202-24-000036","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000036/edgardoc.xml","form_type":"4"}},{"id":1677180,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-01-18T21:02:18.000Z","date":"2024-01-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":354,"price":932.34,"value":330048.36,"ownership":{"direct":true},"balance_after":22984,"source":{"system":"sec-edgar","filing":"0001968202-24-000036","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000036/edgardoc.xml","form_type":"4"}},{"id":1677179,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-01-18T21:02:18.000Z","date":"2024-01-17","kind":"exercise","planned":false,"acquired":true,"shares":500,"price":378.98,"value":189490.0,"ownership":{"direct":true},"balance_after":23338,"source":{"system":"sec-edgar","filing":"0001968202-24-000036","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000036/edgardoc.xml","form_type":"4"}},{"id":1678529,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-01-17T21:03:43.000Z","date":"2024-01-12","kind":"exercise","planned":false,"acquired":false,"shares":800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":14687,"derivative":{"exercise_price":378.98,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":800},"source":{"system":"sec-edgar","filing":"0001968202-24-000034","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000034/edgardoc.xml","form_type":"4"}},{"id":1678528,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-01-17T21:03:43.000Z","date":"2024-01-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":568,"price":928.18,"value":527206.24,"ownership":{"direct":true},"balance_after":22838,"source":{"system":"sec-edgar","filing":"0001968202-24-000034","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000034/edgardoc.xml","form_type":"4"}},{"id":1678527,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-01-17T21:03:43.000Z","date":"2024-01-12","kind":"exercise","planned":false,"acquired":true,"shares":800,"price":378.98,"value":303184.0,"ownership":{"direct":true},"balance_after":23406,"source":{"system":"sec-edgar","filing":"0001968202-24-000034","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000034/edgardoc.xml","form_type":"4"}},{"id":1684818,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-01-08T21:02:01.000Z","date":"2024-01-04","kind":"exercise","planned":false,"acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":15487,"derivative":{"exercise_price":378.98,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001968202-24-000031","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000031/edgardoc.xml","form_type":"4"}},{"id":1684817,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-01-08T21:02:01.000Z","date":"2024-01-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":342,"price":917.05,"value":313631.1,"ownership":{"direct":true},"balance_after":22606,"source":{"system":"sec-edgar","filing":"0001968202-24-000031","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000031/edgardoc.xml","form_type":"4"}},{"id":1684816,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-01-08T21:02:01.000Z","date":"2024-01-04","kind":"exercise","planned":false,"acquired":true,"shares":500,"price":378.98,"value":189490.0,"ownership":{"direct":true},"balance_after":22948,"source":{"system":"sec-edgar","filing":"0001968202-24-000031","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000031/edgardoc.xml","form_type":"4"}},{"id":1689484,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-01-04T21:19:09.000Z","date":"2024-01-03","kind":"exercise","planned":false,"acquired":false,"shares":1100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":15987,"derivative":{"exercise_price":378.98,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":1100},"source":{"system":"sec-edgar","filing":"0001883850-24-000005","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000005/edgardoc.xml","form_type":"4"}},{"id":1689483,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-01-04T21:19:09.000Z","date":"2024-01-02","kind":"exercise","planned":false,"acquired":false,"shares":650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":17087,"derivative":{"exercise_price":378.98,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":650},"source":{"system":"sec-edgar","filing":"0001883850-24-000005","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000005/edgardoc.xml","form_type":"4"}},{"id":1689482,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-01-04T21:19:09.000Z","date":"2024-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":688,"price":912.3,"value":627662.4,"ownership":{"direct":true},"balance_after":22448,"source":{"system":"sec-edgar","filing":"0001883850-24-000005","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000005/edgardoc.xml","form_type":"4"}},{"id":1689481,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-01-04T21:19:09.000Z","date":"2024-01-03","kind":"exercise","planned":false,"acquired":true,"shares":1100,"price":378.98,"value":416878.0,"ownership":{"direct":true},"balance_after":23136,"source":{"system":"sec-edgar","filing":"0001883850-24-000005","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000005/edgardoc.xml","form_type":"4"}},{"id":1689480,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-01-04T21:19:09.000Z","date":"2024-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":421,"price":888.34,"value":373991.14,"ownership":{"direct":true},"balance_after":22036,"source":{"system":"sec-edgar","filing":"0001883850-24-000005","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000005/edgardoc.xml","form_type":"4"}},{"id":1689479,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2024-01-04T21:19:09.000Z","date":"2024-01-02","kind":"exercise","planned":false,"acquired":true,"shares":650,"price":378.98,"value":246337.0,"ownership":{"direct":true},"balance_after":22457,"source":{"system":"sec-edgar","filing":"0001883850-24-000005","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000005/edgardoc.xml","form_type":"4"}},{"id":1698252,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-12-29T21:05:59.000Z","date":"2023-12-28","kind":"exercise","planned":false,"acquired":false,"shares":850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":17737,"derivative":{"exercise_price":378.98,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":850},"source":{"system":"sec-edgar","filing":"0001883850-23-000108","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000108/edgardoc.xml","form_type":"4"}},{"id":1698251,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-12-29T21:05:59.000Z","date":"2023-12-27","kind":"exercise","planned":false,"acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":18587,"derivative":{"exercise_price":378.98,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001883850-23-000108","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000108/edgardoc.xml","form_type":"4"}},{"id":1698250,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-12-29T21:05:59.000Z","date":"2023-12-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":612,"price":884.88,"value":541546.56,"ownership":{"direct":true},"balance_after":21807,"source":{"system":"sec-edgar","filing":"0001883850-23-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000108/edgardoc.xml","form_type":"4"}},{"id":1698249,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-12-29T21:05:59.000Z","date":"2023-12-28","kind":"exercise","planned":false,"acquired":true,"shares":850,"price":378.98,"value":322133.0,"ownership":{"direct":true},"balance_after":22419,"source":{"system":"sec-edgar","filing":"0001883850-23-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000108/edgardoc.xml","form_type":"4"}},{"id":1698248,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-12-29T21:05:59.000Z","date":"2023-12-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":542,"price":872.21,"value":472737.82,"ownership":{"direct":true},"balance_after":21569,"source":{"system":"sec-edgar","filing":"0001883850-23-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000108/edgardoc.xml","form_type":"4"}},{"id":1698247,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-12-29T21:05:59.000Z","date":"2023-12-27","kind":"exercise","planned":false,"acquired":true,"shares":750,"price":378.98,"value":284235.0,"ownership":{"direct":true},"balance_after":22111,"source":{"system":"sec-edgar","filing":"0001883850-23-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000108/edgardoc.xml","form_type":"4"}},{"id":1711606,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-12-14T21:08:07.000Z","date":"2023-12-13","kind":"exercise","planned":false,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":19337,"derivative":{"exercise_price":378.98,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001883850-23-000100","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000100/edgardoc.xml","form_type":"4"}},{"id":1711605,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-12-14T21:08:07.000Z","date":"2023-12-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":723,"price":871.12,"value":629819.76,"ownership":{"direct":true},"balance_after":21361,"source":{"system":"sec-edgar","filing":"0001883850-23-000100","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000100/edgardoc.xml","form_type":"4"}},{"id":1711604,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-12-14T21:08:07.000Z","date":"2023-12-13","kind":"exercise","planned":false,"acquired":true,"shares":1000,"price":378.98,"value":378980.0,"ownership":{"direct":true},"balance_after":22084,"source":{"system":"sec-edgar","filing":"0001883850-23-000100","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000100/edgardoc.xml","form_type":"4"}},{"id":1711603,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-12-14T21:08:07.000Z","date":"2023-12-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":6381,"price":856.71,"value":5466666.51,"ownership":{"direct":true},"balance_after":21084,"source":{"system":"sec-edgar","filing":"0001883850-23-000100","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000100/edgardoc.xml","form_type":"4"}},{"id":1715272,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-12-12T21:01:38.000Z","date":"2023-12-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":2552,"price":844.09,"value":2154117.68,"ownership":{"direct":true},"balance_after":27465,"source":{"system":"sec-edgar","filing":"0001968202-23-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000051/edgardoc.xml","form_type":"4"}},{"id":1715271,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-12-12T21:01:38.000Z","date":"2023-12-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":669,"price":844.09,"value":564696.21,"ownership":{"direct":true},"balance_after":30017,"source":{"system":"sec-edgar","filing":"0001968202-23-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000051/edgardoc.xml","form_type":"4"}},{"id":1715270,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-12-12T21:01:38.000Z","date":"2023-12-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":1013,"price":843.79,"value":854759.27,"ownership":{"direct":true},"balance_after":30686,"source":{"system":"sec-edgar","filing":"0001968202-23-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000051/edgardoc.xml","form_type":"4"}},{"id":1797079,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-08-25T20:02:53.000Z","date":"2023-08-23","kind":"sale","planned":false,"acquired":false,"shares":223,"price":844,"value":188212.0,"ownership":{"direct":true},"balance_after":31699,"source":{"system":"sec-edgar","filing":"0001968202-23-000030","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000030/edgardoc.xml","form_type":"4"}},{"id":1936140,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-27","kind":"exercise","planned":true,"acquired":false,"shares":800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":381.92,"expiration_date":"2026-12-16","underlying":"Common Stock","underlying_shares":800},"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936139,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-27","kind":"exercise","planned":true,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":20337,"derivative":{"exercise_price":378.98,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936138,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-28","kind":"sale","planned":true,"acquired":false,"shares":31,"price":826.36,"value":25617.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."}],"balance_after":31922,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936137,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-28","kind":"sale","planned":true,"acquired":false,"shares":243,"price":825.37,"value":200564.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 243 shares of Company stock on March 28, 2023 at prices ranging from $825.02 to $825.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 28, 2023 at each separate price."}],"balance_after":31953,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936136,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-28","kind":"sale","planned":true,"acquired":false,"shares":157,"price":824.54,"value":129452.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 157 shares of Company stock on March 28, 2023 at prices ranging from $824.00 to $824.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 28, 2023 at each separate price."}],"balance_after":32196,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936135,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-28","kind":"sale","planned":true,"acquired":false,"shares":181,"price":823.6,"value":149071.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 181 shares of Company stock on March 28, 2023 at prices ranging from $823.02 to $823.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 28, 2023 at each separate price."}],"balance_after":32353,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936134,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-28","kind":"sale","planned":true,"acquired":false,"shares":128,"price":822.67,"value":105301.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 128 shares of Company stock on March 28, 2023 at prices ranging from $822.21 to $822.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 28, 2023 at each separate price."}],"balance_after":32534,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936133,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-28","kind":"sale","planned":true,"acquired":false,"shares":142,"price":821.4,"value":116638.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 142 shares of Company stock on March 28, 2023 at prices ranging from $821.04 to $821.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 28, 2023 at each separate price."}],"balance_after":32662,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936132,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-28","kind":"sale","planned":true,"acquired":false,"shares":115,"price":820.85,"value":94397.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 115 shares of Company stock on March 28, 2023 at prices ranging from $820.67 to $820.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 28, 2023 at each separate price."}],"balance_after":32804,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936131,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-28","kind":"sale","planned":true,"acquired":false,"shares":10,"price":818.81,"value":8188.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."}],"balance_after":32919,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936130,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-27","kind":"sale","planned":true,"acquired":false,"shares":7,"price":830.01,"value":5810.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."}],"balance_after":32929,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936129,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-27","kind":"sale","planned":true,"acquired":false,"shares":4,"price":829.16,"value":3316.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."}],"balance_after":32936,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936128,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-27","kind":"sale","planned":true,"acquired":false,"shares":13,"price":825.59,"value":10732.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."}],"balance_after":32940,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936127,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-27","kind":"sale","planned":true,"acquired":false,"shares":4,"price":824.3,"value":3297.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."}],"balance_after":32953,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936126,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-27","kind":"sale","planned":true,"acquired":false,"shares":18,"price":822.57,"value":14806.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 18 shares of Company stock on March 27, 2023 at prices ranging from $822.46 to $822.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 27, 2023 at each separate price."}],"balance_after":32957,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936125,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-27","kind":"sale","planned":true,"acquired":false,"shares":48,"price":821.39,"value":39426.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 48 shares of Company stock on March 27, 2023 at prices ranging from $821.02 to $821.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 27, 2023 at each separate price."}],"balance_after":32975,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936124,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-27","kind":"sale","planned":true,"acquired":false,"shares":50,"price":820.46,"value":41023.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 50 shares of Company stock on March 27, 2023 at prices ranging from $820.00 to $820.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 27, 2023 at each separate price."}],"balance_after":33023,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936123,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-27","kind":"sale","planned":true,"acquired":false,"shares":39,"price":819.47,"value":31959.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 39 shares of Company stock on March 27, 2023 at prices ranging from $819.34 to $819.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 27, 2023 at each separate price."}],"balance_after":33073,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936122,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-27","kind":"tax_withholding","planned":true,"acquired":false,"shares":2204,"price":825.17,"value":1818674.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."}],"balance_after":33112,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936121,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-27","kind":"exercise","planned":true,"acquired":true,"shares":3000,"price":378.98,"value":1136940.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."}],"balance_after":35316,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936120,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-27","kind":"tax_withholding","planned":true,"acquired":false,"shares":589,"price":825.17,"value":486025.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."}],"balance_after":32316,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":1936119,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-03-29T20:07:07.000Z","date":"2023-03-27","kind":"exercise","planned":true,"acquired":true,"shares":800,"price":381.92,"value":305536.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023."}],"balance_after":32905,"source":{"system":"sec-edgar","filing":"0001968202-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000004/edgardoc.xml","form_type":"4"}},{"id":2029483,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-03","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":800,"derivative":{"exercise_price":381.92,"expiration_date":"2026-12-16","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029482,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":28,"price":797.43,"value":22328.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":32105,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029481,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":18,"price":796.43,"value":14335.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 18 shares of Company stock on February 6, 2023 at prices ranging from $796.35 to $796.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price."}],"balance_after":32133,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029480,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":59,"price":795.41,"value":46929.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 59 shares of Company stock on February 6, 2023 at prices ranging from $795.26 to $795.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price."}],"balance_after":32151,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029479,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":99,"price":794.61,"value":78666.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 99 shares of Company stock on February 6, 2023 at prices ranging from $794.28 to $794.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price."}],"balance_after":32210,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029478,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":2,"price":793.33,"value":1586.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":32309,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029477,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":3,"price":791,"value":2373.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":32311,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029476,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":10,"price":790.41,"value":7904.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":32314,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029475,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":49,"price":789.05,"value":38663.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":32324,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029474,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":99,"price":788.62,"value":78073.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 99 shares of Company stock on February 6, 2023 at prices ranging from $788.48 to $788.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price."}],"balance_after":32373,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029473,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":58,"price":787.47,"value":45673.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":32472,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029472,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":85,"price":786.45,"value":66848.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 85 shares of Company stock on February 6, 2023 at prices ranging from $786.03 to $786.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price."}],"balance_after":32530,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029471,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":78,"price":785.88,"value":61298.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 78 shares of Company stock on February 6, 2023 at prices ranging from $785.85 to $785.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price."}],"balance_after":32615,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029470,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":113,"price":784.27,"value":88622.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 113 shares of Company stock on February 6, 2023 at prices ranging from $784.02 to $784.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price."}],"balance_after":32693,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029469,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":51,"price":783.05,"value":39935.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":32806,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029468,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-03","kind":"tax_withholding","acquired":false,"shares":2248,"price":774.29,"value":1740603.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":32857,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029467,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-03","kind":"exercise","acquired":true,"shares":3000,"price":381.92,"value":1145760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":35105,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2029466,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2023-02-07T21:09:21.000Z","date":"2023-02-03","kind":"sale","acquired":false,"shares":739,"price":764.5,"value":564965.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":32105,"source":{"system":"sec-edgar","filing":"0001883850-23-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000035/edgardoc.xml","form_type":"4"}},{"id":2080310,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-12-20T21:07:02.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":14222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":14222,"derivative":{"exercise_price":726.53,"expiration_date":"2032-12-16","underlying":"Common Stock","underlying_shares":14222},"source":{"system":"sec-edgar","filing":"0001883850-22-000132","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000132/edgardoc.xml","form_type":"4"}},{"id":2080309,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2022-12-20T21:07:02.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":3853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 16, 2024 and 50% on December 16, 2026."}],"balance_after":32844,"source":{"system":"sec-edgar","filing":"0001883850-22-000132","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000132/edgardoc.xml","form_type":"4"}},{"id":2090477,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-12-12T21:34:35.000Z","date":"2022-12-08","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":3800,"derivative":{"exercise_price":381.92,"expiration_date":"2026-12-16","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001883850-22-000107","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000107/edgardoc.xml","form_type":"4"}},{"id":2090476,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2022-12-12T21:34:35.000Z","date":"2022-12-09","kind":"tax_withholding","acquired":false,"shares":492,"price":753.28,"value":370613.76,"ownership":{"direct":true},"balance_after":28991,"source":{"system":"sec-edgar","filing":"0001883850-22-000107","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000107/edgardoc.xml","form_type":"4"}},{"id":2090475,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2022-12-12T21:34:35.000Z","date":"2022-12-08","kind":"tax_withholding","acquired":false,"shares":2261,"price":768.54,"value":1737668.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":29483,"source":{"system":"sec-edgar","filing":"0001883850-22-000107","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000107/edgardoc.xml","form_type":"4"}},{"id":2090474,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2022-12-12T21:34:35.000Z","date":"2022-12-08","kind":"exercise","acquired":true,"shares":3000,"price":381.92,"value":1145760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":31744,"source":{"system":"sec-edgar","filing":"0001883850-22-000107","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000107/edgardoc.xml","form_type":"4"}},{"id":2099118,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-12-02T21:05:43.000Z","date":"2022-12-01","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":6800,"derivative":{"exercise_price":381.92,"expiration_date":"2026-12-16","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001883850-22-000102","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000102/edgardoc.xml","form_type":"4"}},{"id":2099117,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2022-12-02T21:05:43.000Z","date":"2022-12-02","kind":"sale","acquired":false,"shares":12,"price":760.19,"value":9122.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":28744,"source":{"system":"sec-edgar","filing":"0001883850-22-000102","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000102/edgardoc.xml","form_type":"4"}},{"id":2099116,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":43928,"kind":"person","name":"Landry Robert E","position":1,"cik":"0001585160","reported_name":"Landry Robert E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2022-12-02T21:05:43.000Z","date":"2022-12-02","kind":"sale","acquired":false,"shares":16,"price":759.9,"value":12158.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":28756,"source":{"system":"sec-edgar","filing":"0001883850-22-000102","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000102/edgardoc.xml","form_type":"4"}}],"next_cursor":"2022-12-02T21:05:43.000000Z,2099116"}